Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study

NCT07634263 | Not Yet Recruiting DMC

• 1 other identifier: Ready4Home
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 3

Brief Summary

Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing. Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood. This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment. The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.

Conditions

Multiple Myeloma Progression; Multiple Myeloma Refractory; Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Keywords

Hematologic Neoplasms; multiple myeloma; Home Care Services; Patient Acceptance of Health Care

Outcome Measures

Primary Outcomes (3)

• Perceptions - patient

  Semi-structured interviews with patients at inclusion

  Day 1

• Perception - caregivers

  Semi-structured interviews with caregiver (together with patient) at inclusion

  Day 1

• Perception - Healthcare staff

  Focus group interview with Healthcare staff at end of study (after inclusion of all patients) in regards to barriers and possibilities in home administration

  At study completion (end of inclusion of all patients)

Secondary Outcomes (28)

• Biological sex

  Day 1

• Patient reported outcomes

  Day 1

• Patient Reported Outcome

  Day 1

• Caregiver burden

  Day 1

• Age

  Day 1

Study Arms (3)

Patients enrolled in a Treat@Home study

Patients who are enrolled in one of the two Treat@Home studies will be invited to participate

Patients declining enrollment in a Treat@Home study

Patients who are invited in one of the two Treat@Home studies but decline this invitation will be invited to participate

Patients deemed not eligible for enrollment in a Treat@Home study

Patients deemed not eligible for enrollment in one of the two Treat@Home studies will be invited for enrollment

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients from the Department of Hematology at Odense University Hospital and Zealand University Hospital who are enrolled in the two Treat@Home studies will be invited to participate, including those who accept, decline, or are deemed ineligible for home-based treatment. We aim to include 50 participants, with 25 recruited from each site.

You may qualify if:

• \>=18 years old
• diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine.

You may not qualify if:

• \- Dementia, psychotic disorders, or other cognitive impairments limiting participation.

Sponsors & Collaborators

• Odense University Hospital: lead

Study Sites (3)

Copenhagen University Hospital (Rigshospitalet)

Copenhagen, 2100, Denmark

Location

Odense University Hospital

Odense, 5000, Denmark

Location

Sjællands Universitets Hospital

Roskilde, 4000, Denmark

Location

MeSH Terms

Conditions

Multiple Myeloma; Lymphoma; Hematologic Neoplasms; Patient Acceptance of Health Care

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Lymphatic Diseases; Neoplasms by Site; Treatment Adherence and Compliance; Health Behavior; Behavior

Central Study Contacts

Jannie Kirkegaard, RN

CONTACT

+45 29648494; jannie.kirkegaard@rsyd.dk

Kristina Nørskov, RN, PhD

CONTACT

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2026
• First Posted: June 8, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2028
• Last Updated: June 8, 2026

Record last verified: 2026-06

Locations

DK (3)